The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta(TM)) is a new generation multi-targeted antifola...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche, Michael, Parisi, Laura, Li, Linda, Knehans, Amy, Phaeton, Rebecca, Kesterson, Joshua P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007165/
https://www.ncbi.nlm.nih.gov/pubmed/29983902
http://dx.doi.org/10.4081/oncol.2018.346
_version_ 1783332981655470080
author Roche, Michael
Parisi, Laura
Li, Linda
Knehans, Amy
Phaeton, Rebecca
Kesterson, Joshua P.
author_facet Roche, Michael
Parisi, Laura
Li, Linda
Knehans, Amy
Phaeton, Rebecca
Kesterson, Joshua P.
author_sort Roche, Michael
collection PubMed
description Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta(TM)) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.
format Online
Article
Text
id pubmed-6007165
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-60071652018-07-06 The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review Roche, Michael Parisi, Laura Li, Linda Knehans, Amy Phaeton, Rebecca Kesterson, Joshua P. Oncol Rev Review Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta(TM)) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer. PAGEPress Publications, Pavia, Italy 2018-03-21 /pmc/articles/PMC6007165/ /pubmed/29983902 http://dx.doi.org/10.4081/oncol.2018.346 Text en ©Copyright M. Roche et al., 2018 http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).
spellingShingle Review
Roche, Michael
Parisi, Laura
Li, Linda
Knehans, Amy
Phaeton, Rebecca
Kesterson, Joshua P.
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
title The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
title_full The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
title_fullStr The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
title_full_unstemmed The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
title_short The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
title_sort role of pemetrexed in recurrent epithelial ovarian cancer: a scoping review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007165/
https://www.ncbi.nlm.nih.gov/pubmed/29983902
http://dx.doi.org/10.4081/oncol.2018.346
work_keys_str_mv AT rochemichael theroleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT parisilaura theroleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT lilinda theroleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT knehansamy theroleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT phaetonrebecca theroleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT kestersonjoshuap theroleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT rochemichael roleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT parisilaura roleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT lilinda roleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT knehansamy roleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT phaetonrebecca roleofpemetrexedinrecurrentepithelialovariancancerascopingreview
AT kestersonjoshuap roleofpemetrexedinrecurrentepithelialovariancancerascopingreview

Ejemplares similares